Compare ARK Genomic Revolution ETF (ARKG) vs Sibanye Stillwater Ltd (SBSW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Sibanye Stillwater Ltd — how do they compare? ARK Genomic Revolution ETF trades at $40.83, while Sibanye Stillwater Ltd trades at $8.61 (market cap $5.95B). The key difference: Sibanye Stillwater Ltd pays a 3.64% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Sibanye Stillwater Ltd nearer its low. Which is the better fit depends on your goals.
| ARKG | SBSW | |
|---|---|---|
Sector | Sector/Thematic | Basic Materials |
52-Week High | $43.57 | $21.12 |
52-Week Low | $23.09 | $7.27 |
Market Cap | — | $5.95B |
Enterprise Value | — | $7.57B |
Dividend Yield | — | 3.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Sibanye Stillwater (SBSW) trades at $8.55, down 0.12% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $7.30 billion in 2024, though revenue stabilized at $112.13 billion. Recent news highlights a potential turnaround with EBITDA growth and debt reduction plans, while analyst consensus is mixed with 42.9% buy ratings.
The outlook hinges on operational improvements and commodity price recovery. Key risks include persistent negative margins and high debt levels, but low valuation multiples may attract value investors if the company executes its turnaround strategy effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →
